MAP2K7 and fibrosis: Nevertheless, our work puts MEK center stage in fibrotic ECM remodeling and the Mirdametinib (PD-0325901) MEK inhibitor that was effective and not cytotoxic in our study may represent a candidate therapeutic approach for fibrosis patients.